Clostridium difficile in paediatric populations

被引:8
|
作者
Allen, Upton D. [1 ]
机构
[1] Canadian Paediat Soc, Infect Dis & Immunizat Comm, Ottawa, ON K1G 4J8, Canada
关键词
CDI; Colitis; Diarrhea; Immunocompromise; Megacolon; Metronidazole; NAP1; Vancomycin; PROTON PUMP INHIBITORS; MULTICENTER EVALUATION; FECAL BACTERIOTHERAPY; CONTROLLED-TRIAL; CYTOTOXIN ASSAY; UNITED-STATES; FUSIDIC ACID; RISK-FACTORS; DIARRHEA; INFECTION;
D O I
10.1093/pch/19.1.43
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
An increase in Clostridium difficile infection incidence has been observed among hospitalized children in the United States. The present statement, targeted at clinicians caring for infants and children in community and institutional settings, summarizes the relevant information relating to the role of C difficile in childhood diarrhea and provides recommendations for diagnosis, prevention and treatment. Significant differences between adult and paediatric risk factors and disease are discussed, along with emerging therapies. The relationship between age and disease severity in children with a newly emergent and more fluoroqinolone-resistant strain of C difficile (North American Pulse-field type-1 [NAP1]) remains unknown. The importance of antimicrobial stewardship as a preventive strategy is highlighted. This statement replaces a previous Canadian Paediatric Society position statement on C difficile published in 2000.
引用
收藏
页码:43 / 48
页数:6
相关论文
共 50 条
  • [11] Systematic Review of Current Treatment and Prevention Strategies for Clostridium difficile
    Parmar, Nicholas V.
    Glauser, Jonathan
    CURRENT EMERGENCY AND HOSPITAL MEDICINE REPORTS, 2019, 7 (03) : 66 - 73
  • [12] Advances in the treatment of Clostridium difficile with fidaxomicin: a narrow spectrum antibiotic
    Sears, Pamela
    Ichikawa, Yoshi
    Ruiz, Nancy
    Gorbach, Sherwood
    PHARMACEUTICAL SCIENCE TO IMPROVE THE HUMAN CONDITION: PRIX GALIEN USA 2012, 2013, 1291 : 33 - 41
  • [13] Clinical and demographic profile and risk factors for Clostridium difficile infection
    Carvajal, Carlos
    Pacheco, Carlos
    Jaimes, Fabian
    BIOMEDICA, 2017, 37 (01): : 53 - 61
  • [14] Clostridium difficile infection: a review of the literature
    Khan, Fahmi Yousef
    Elzouki, Abdul-Naser
    ASIAN PACIFIC JOURNAL OF TROPICAL MEDICINE, 2014, 7 : S6 - S13
  • [15] Clostridium Difficile and Inflammatory Bowel Disease
    Ananthakrishnan, Ashwin N.
    Issa, Mazen
    Binion, David G.
    GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2009, 38 (04) : 711 - +
  • [16] Therapies on the horizon for Clostridium difficile infections
    McFarland, Lynne V.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2016, 25 (05) : 541 - 555
  • [17] The impact of pseudomembrane formation on the outcome of Clostridium difficile-associated disease
    Berdichevski, T.
    Keller, N.
    Rahav, G.
    Bar-Meir, S.
    Eliakim, R.
    Ben-Horin, S.
    INFECTION, 2013, 41 (05) : 969 - 977
  • [18] Pharmacodynamic studies of vancomycin, metronidazole and fusidic acid against Clostridium difficile
    Odenholt, Inga
    Walder, Mats
    Wullt, Marlene
    CHEMOTHERAPY, 2007, 53 (04) : 267 - 274
  • [19] Current State of Clostridium difficile Treatment Options
    Venugopal, Anilrudh A.
    Johnson, Stuart
    CLINICAL INFECTIOUS DISEASES, 2012, 55 : S71 - S76
  • [20] Clostridium difficile in Solid Organ Transplant Recipients
    Dubberke, E. R.
    Riddle, D. J.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 : S35 - S40